Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr

  • Posted by: Biocon Biologics

Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Recognized among World’s Top 20 Inspirational Leaders in Biopharmaceuticals in The Medicine Maker ‘Power List 2020’

  • Posted by: Biocon Biologics

Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia

  • Posted by: Biocon Biologics

Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers

  • Posted by: Biocon Biologics

Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S.

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Bevacizumab for Review

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - matadorbet güncel adres - onwin